Proton Rahman

Sep 1, 2023 | jrheum.org | Louis Bessette |Proton Rahman |John Kelsall |Jane Purvis

Real-World Incidence and Determinants of Infection in Patients With Rheumatoid Arthritis Treated With Golimumab After a Median Follow-Up Time of 27 Months Louis Bessette, Proton Rahman, John Kelsall, Jane Purvis, Emmanouil Rampakakis, Allen J. Lehman, Meagan Rachich, Francois Nantel, Odalis Asin-Milan, A. Marilise Marrache The Journal of Rheumatology Sep 2023, 50 (9) 1121-1126; DOI: 10.3899/jrheum.2022-1283

Jun 1, 2023 | jrheum.org | Proton Rahman |Wolf-Henning Boehncke |Philip Mease |Alice Gottlieb

DISCUSSIONThese findings represent the most comprehensive safety assessment of an IL-23p19 inhibitor in PsA that we know of to date, with 1508 patients evaluated for up to 2 years (2125 PY). Integrated analyses across 4 phase II/III studies of patients with active PsA demonstrated that the safety profile of GUS remained consistent, regardless of prior TNFi or concomitant MTX use.

Feb 8, 2023 | jrheum.org | Proton Rahman |Wolf-Henning Boehncke |Philip Mease |Alice Gottlieb

Thank you for your interest in spreading the word about The Journal of Rheumatology. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.